NOV 29, 2015 10:30 AM PST

New Molecule Shrinks Melanoma Tumors and Prevents Relapse

WRITTEN BY: Xuan Pham
Researchers at Sanford Burnham Prebys Medical Discovery Institute announced the discovery of a new anti-cancer compound, named SBI-756, that can halt the growth of melanoma tumors.
 
Melanoma is a deadly form of skin cancer caused by ultraviolet radiation damages to the skin cells. According to the Skin Cancer Foundation, melanoma kills an estimated 9,940 Americans each year.
 
Melanoma is the deadliest form of skin cancer.

While melanoma can be curable if treated early, some forms of melanomas can adapt and quickly become resistant to today’s leading cancer regimens. In about 50% of patients, melanomas are caused by mutations in the BRAF gene, which makes proteins for cell growth. Currently, the Food and Drug Administration has approved one anti-cancer drug, Vemurafenib, for BRAF-induced melanomas. However, despite early tumor shrinkage, some patients inevitably relapse as the tumor cells become resistant to Vemurafenib. For these patients, there hasn’t been another alternative.
 
The newly discovered compound, SBI-756, has a different target than the conventional Vemurafenib. Instead of inhibiting the BRAF gene, SBI-756 targets cell growth at the start of translation. Specifically, SBI-756 targets the eukaryotic initiation factor 4G1 (also known as eIF4G1) in the translation initiation complex. Every cell depends on the translation machinery to convert mRNA messages into protein products. So, in effect, SBI-756 stops cell growth at its roots, making it a first-in-class drug. 
 
"The unique target of SBI-756 makes it especially promising for use in combination therapy," said Ze'ev Ronai, senior author of the study. "A major issue limiting the effectiveness of current melanoma therapies is that tumors become resistant to treatment. Combining drugs that come at a melanoma from different angles may help overcome the problem of drug resistance."
 
Indeed, SBI-756 slowed the growth of BRAF mutant melanomas in cells. In mice, the drug delayed onset and decreased the number of melanoma tumors. When the researchers co-administered SBI-756 with Vemurafenib, they reported that tumors shrank and did not reoccur. Taken together, the data suggests that SBI-756 has great potential to treat resistant and unresponsive BRAF-induced tumors.
 
"The ability of this compound to delay or eliminate the formation of resistant melanomas is very exciting," said Ronai.
 
 The team also reported that efficacy of the compound could be attained with relatively low doses. Furthermore, even when the compound was given to mice over a long amount of time, the team did not find any evidence of toxicity.
 
The SBI-756 was the product of over seven years of research. But Ronai and his team still have additional tweaking to do before the compound is ready for human clinical trials. And because SBI-756 targets the translation machinery, a fundamental component for cell growth, the team is looking to apply the compound to other tumors. 
 
"We hope that we're going to come up with the next generation of the compound that can go into clinical trials--first in melanoma but likely in other tumors," Ronai said.
 
Watch the video to learn the warning signs of melanomas. 
 

Sources: Cancer Research, EurekAlert
About the Author
I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUL 01, 2022
Clinical & Molecular DX
Could Temperature Fight Obesity? Study in Mice Suggests Cold Exposure Could
JUL 01, 2022
Could Temperature Fight Obesity? Study in Mice Suggests Cold Exposure Could
Mammals, including humans, have at least two different types of fat tissue. White fat is the tissue where energy is prim ...
JUL 13, 2022
Clinical & Molecular DX
Nipah Virus: Moderna Invests in a Vaccine for the Virus that Fauci Calls a 'Pandemic Threat'
JUL 13, 2022
Nipah Virus: Moderna Invests in a Vaccine for the Virus that Fauci Calls a 'Pandemic Threat'
In Malaysia in the fall of 1998, a mystery ailment swept through the local pig-farming community, eventually leading to ...
JUL 23, 2022
Health & Medicine
Detecting Covert Consciousness with EEG and Artificial Intelligence
JUL 23, 2022
Detecting Covert Consciousness with EEG and Artificial Intelligence
For those who appear totally unresponsive, researchers have discovered that signs of covert consciousness or subtle brai ...
AUG 04, 2022
Clinical & Molecular DX
Artificial Intelligence Shows Promise in Diagnosing Strokes
AUG 04, 2022
Artificial Intelligence Shows Promise in Diagnosing Strokes
Quick identification and intervention is critical in successfully treating a stroke. During a stroke, blood supply to th ...
JUL 31, 2022
Technology
Sticker Worn on the Skin Produces Continuous Ultrasound Images
JUL 31, 2022
Sticker Worn on the Skin Produces Continuous Ultrasound Images
Ultrasound technology has been a revolutionary tool used to diagnose conditions and get a better understanding of what&r ...
AUG 04, 2022
Health & Medicine
Parechovirus Infections are Increasing in Infants
AUG 04, 2022
Parechovirus Infections are Increasing in Infants
This year, 29 infants have been admitted to the Children's Hospital at Vanderbilt University Medical Center with human p ...
Loading Comments...